Efficacy of a Brief Intervention to Improve Sexual and Gender Minorities' Mental Health: Randomized Controlled Trial.

NCT05349877 | Unknown DMC

• 2 other identifiers: PUCRSBR-1009839059120.0.0000.5336
• Study Type: interventional
• Target: 306
• Locations: 0 countries
• Sites: N/A

Brief Summary

Experiences of violence, from micro to physical aggressions, have a deleterious impact on mental health. According to the Minority Stress Theory, unfavorable social conditions (such as anticipated and experienced discrimination and internalized homophobia), mediated by resilience strategies, can lead to mental health or illness. Sexual and gender minorities (SGM) face stigma and discrimination aggravating multiple aspects of their lives: from school drop-out to halting health care access. SGM reveal avoiding medical assistance for fear of discrimination while health professionals disclose feeling unprepared to handle SGM health needs. There are two main challenges: 1) developing specific psychological interventions to reduce the impact of stigma and discrimination on SGM' mental health; and 2) training public health professionals to properly address SGM needs. Therefore, the present trial aims to assess the efficacy of a brief, self-guided, on-line, asynchronous and unsupervised psychological intervention in improving SGM' mental health.

Conditions

Depression; Anxiety; Psychological Distress; Social Phobia; Post Traumatic Stress Disorder; Suicidal Ideation; Sex, Unsafe; Discrimination, Social; Behavior, Risk; Self Esteem

Outcome Measures

Primary Outcomes (7)

• Change from baseline depression at 3 and 6 moths after the intervention.

  Assessed using the Center for Epidemiologic Studies - Depression (CES-D). CES-D is composed of 20 items. The final score ranges from 0 to 60 points. Originally, the cutoff point of the CES-D scale to identify the presence of depressive symptoms is equal or higher 16 points. However, when considering Brazilian samples, the cutoff point of equal or higher 12 points was proposed.

  Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).

• Change from baseline anxiety at 1 week, and 3 and 6 moths after the intervention.

  Evaluated using the Generalized Anxiety Disorder 7-item (GAD-7). The GAD-7 consists of 7 questions based in part on the DSM-IV criteria for GAD and reflects the frequency of symptoms during the preceding 2-week period. The GAD-7 requires approximately 1-2 minutes to administer and for each symptom queried provides the following response options: "not at all," "several days," "over half the days" and "nearly every day" and these are scored, respectively, as 0, 1, 2 or 3. A score of 10 or greater on the GAD-7 represents a reasonable cut point for identifying cases of GAD.

  Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).

• Change from baseline social phobia at 1 week, and 3 and 6 moths after the intervention.

  Evaluated using the Social Avoidance and Distress Scale (SADS). SADS is a 28 item true/false scale that measures measures aspects of social anxiety including distress, discomfort, fear and avoidance. A total score on the SADS is obtained based on the answers to the true/false questions. Higher scores indicate greater social anxiety.

  Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).

• Change from baseline post-traumatic stress at 1 week, and 3 and 6 moths after the intervention.

  Post-Traumatic Stress Disorder Checklist - Civilian Version (PCL-C). The PCL-C is a 17-item self-report checklist of PTSD symptoms based closely on the DSM-IV criteria. The score consists in adding up all items from each of the 17 items for a total severity score (range = 17-85). The cut off 17-29 shows little to no severity, 28-29 suggests some PTSD symptom, 30-44 moderate to moderately high severity of PTSD symptoms, and 45-85 high severity of PTSD symptoms.

  Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).

• Change from baseline on suicide ideation at 3 and 6 moths after the intervention.

  Patient Health Questionnaire-9 (PHQ-9). The PHQ-9 is a clinically-validated screening tool that healthcare providers use to screen for depression, and also to diagnose and monitor the severity of the condition. A PHQ-9 score total of 0-4 points equals "normal" or minimal depression. Scoring between 5-9 points indicates mild depression, 10-14 points indicates moderate depression, 15-19 points indicates moderately severe depression, and 20 or more points indicates severe depression.

  Baseline (T0), three months after the intervention (T2), and six the intervention (T3).

• Change from baseline on substance use at 3 and 6 moths after the intervention.

  Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) is an 8 questions tool that detects substance use and related problems. A 'global continuum of risk score' (or total substance involvement) is calculated by the addition of all items for all substances on the ASSIST and has a maximum score of 208.

  Baseline (T0), three months after the intervention (T2), and six the intervention (T3).

• Change from baseline on sex risk behaviors at 3 and 6 moths after the intervention.

  Inquired using yes-no questions concerning unprotected intercourse and multiple sex partners, as well as the Perceived Risk of HIV Scale. Perceived Risk of HIV Scale is a self-report 8-item measure developed to assess how people think and feel about their risk of HIV infection based on their previous sexual behavior and covering several dimensions of perceived HIV risk. Higher scores are associated with a greater number of sex partners, episodes of unprotected sex and having sex while high.

  Baseline (T0), three months after the intervention (T2), and six the intervention (T3).

Secondary Outcomes (2)

• Change from baseline on resilience at 1 week, and 3 and 6 moths after the intervention.

  Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).

• Change from baseline on self-esteem at 1 week, and 3 and 6 moths after the intervention.

  Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).

Study Arms (3)

Expressive writing

EXPERIMENTAL

Participants will be invited to join three writing activities, lasting 20 minutes daily in D1, D3, and D5 of the same week. For example, to write about a difficult or painful experience related discrimination and their feelings about it.

Behavioral: Expressive writing

Self-affirmation

EXPERIMENTAL

Aiming to build self-efficacy, participants will be invite to writing, during 20 minutes daily in D1, D3, and D5 of the same week, a letter to a sexual and gender minority peer suffering from stigma and discrimination.

Behavioral: Self-affirmation

Placebo

PLACEBO COMPARATOR

Participants will be instruct to write about their daily routine, during 20 minutes daily in D1, D3, and D5 of the same week.

Behavioral: Placebo

Interventions

Expressive writing BEHAVIORAL

Write, continuously for 20 minutes, about deepest emotions and thoughts concerning experiences of minority stress, exploring a particular event and how it has affected the participant.

Expressive writing

Self-affirmation BEHAVIORAL

Write, continuously for 20 minutes, about values the participant think is important to overcome experiences of minority stress.

Self-affirmation

Placebo BEHAVIORAL

Write, continuously for 20 minutes, about their daily routine, without expressing feelings and deep thoughts about it.

Placebo

Eligibility Criteria

• Age: 16 Years - 100 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Self-identity as sexual and gender minority.
• Being older than 16 years old.
• Have a stable on-line connection for, at least, 20 minutes in a place where won't be disturbed.
• Reports, in the baseline survey, previous experiences of discrimination, having depression or anxiety symptoms.
• Currently living in Rio Grande do Sul.

You may not qualify if:

• Disagrees with the consent form.

Sponsors & Collaborators

• Pontificia Universidade Católica do Rio Grande do Sul: lead

MeSH Terms

Conditions

Depression; Anxiety Disorders; Phobia, Social; Stress Disorders, Post-Traumatic; Suicidal Ideation; Unsafe Sex; Social Discrimination; Risk-Taking

Condition Hierarchy (Ancestors)

Behavioral Symptoms; Behavior; Mental Disorders; Phobic Disorders; Stress Disorders, Traumatic; Trauma and Stressor Related Disorders; Suicide; Self-Injurious Behavior; Sexual Behavior; Social Behavior

Central Study Contacts

Angelo B Costa, PhD

CONTACT

+55 51 98405-4408; angelobrandellicosta@gmail.com

Anna Martha Fontanari

CONTACT

+55 51 99111-1771; annamarthavf@gmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Randomized, double-blind, clinical trial assessing the efficacy of a brief, unsupervised, self-guided psychological intervention targeting sexual and gender minorities' mental health.

Study Record Dates

• First Submitted: March 11, 2022
• First Posted: April 27, 2022
• Study Start: June 10, 2022
• Primary Completion: June 30, 2022
• Study Completion: December 15, 2022
• Last Updated: April 27, 2022

Record last verified: 2021-10

Data Sharing

• IPD Sharing: Will not share